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Abstract
Background: ART is a multi-centre randomised trial of cardiac surgery which provided a unique opportunity to
evaluate the data from a large number of centres from a variety of countries. We attempted to assess data quality,
including recruitment rates, timeliness and completeness of the data obtained from the centres in different socio-
economic strata.
Methods: The analysis was based on the 2-page CRF completed at the 6 week follow-up. CRF pages were
categorised into “clean” (no edit query) and “dirty” (any incomplete, inconsistent or illegible data). The timelines
were assessed on the basis of the time interval from the visit and receipt of complete CRF. Data quality was
defined as the number of data queries (in percent) and time delay (in days) between visit and receipt of correct
data. Analyses were stratified according to the World Bank definitions into: “Developing” countries (Poland, Brazil
and India) and “Developed” (Italy, UK, Austria and Australia).
Results: There were 18 centres in the “Developed” and 10 centres in the “Developing” countries. The rate of
enrolment did not differ significantly by economic level ("Developing":4.1 persons/month, “Developed":3.7 persons/
month). The time interval for the receipt of data was longer for “Developing” countries (median:37 days) compared
to “Developed” ones (median:11 days) (p < 0.001). The median number of data queries was 23% in “Developed”
countries compared to 19% in “Developing” ones (p = ns).
Conclusions: In this study we showed that data quality was comparable between centres from “Developed” and
“Developing” countries. Data was received in a less timely fashion from Developing countries and appropriate
systems should be instigated to minimize any delays. Close attention should be paid to the training of centres and
to the central management of data quality.
Trial registration: ISRCTN46552265
Background
International multi-centre randomised trials are widely
used to evaluate new investigational medicinal products
or treatment strategies. It is essential that only accurate
and verified data are collected in these trials in order
that the results are reliable particularly as this may be
used to inform guidance and recommendations for
everyday clinical practise. However the collection of
h i g hq u a l i t yd a t ai nt h e s et r i a l sc a nb ec h a l l e n g i n g
because of several potential difficulties e.g. the inclusion
of multiple centres with different research experience,
different cultures and healthcare systems, language diffi-
culties, and the sheer number of people involved in col-
lecting and sending data.
Quality assurance is the key point in all steps of data
management, beginning with data generation and enter-
i n gd a t ao nt oc a s er e p o r tf o r m s( C R F )b yc e n t r e s ,a n d
ending with statistical analysis and presentation of the
results [1]. Data quality can be variable and the purpose
of quality assurance is not only to ensure that all data
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ment effects are authentic and their estimated magni-
tude is unbiased so that clinical trial results are reliable.
Inappropriate CRF or questionnaire management may
produce bias and a lack of precision in the estimates of
treatment effects [2]. Therefore quality assurance is a
cornerstone in improving data quality [3-5].
Even when systematically controlled, databases in clin-
ical trials may include errors. For example in a multi-
centre clinical trial comparing methods of treatment of
uterine cervical cancer a data accuracy of 81.8% was
found and both problems in data management but also
al a c ko fc l a r i t yo ft h eC R Fw e r et ob l a m e[ 6 ] .N a h me t
al. revealed that the average error rate for published
CRF-to-database comparison audits was on average 14.3
per 10, 000 fields [7]. The issue was also described in
cardiac surgery studies [8,9]. However, often these errors
have been described in registries rather than from ran-
domised clinical trials.
The Arterial Revascularisation Trial (ART) is an inter-
national multi-centre randomised clinical trial designed
to compare single internal mammary artery (IMA) with
bilateral IMA grafting in patients undergoing coronary
artery by-pass graft (CABG) surgery [10]. Since ART is
one of the largest cardiac surgery trials ever to be
undertaken it provides a unique opportunity to evaluate
t h ed a t af r o mal a r g en u m b e ro fc e n t r e sf r o mav a r i e t y
of countries with different socio-economic status and to
perform a systematic analysis of the quality of the data
from the different centres.
Our main aim was to compare the data quality
obtained from the centres in different socio-economic
strata. We wanted to compare the following:
1. Recruitment rates across different sites and relate
this to socio-economic status
2. Time differences for receipt of data at 6 weeks fol-
low-up
3. Completeness of the data assessed by the number of
data queries
Our hypothesis was that neither recruitment rates nor
data quality and time delay in sending the data are
dependent on the socio-economic status of the country
of the participating site.
Methods
ART is a multi-centre two-arm randomised trial
designed to determine if the use of both mammary
arteries during CABG surgery improves survival, and
reduces the chance of recurrent angina and/or the need
for further intervention (including further cardiac sur-
gery or percutaneous coronary intervention) compared
to using one mammary artery. CABG patients with
multi-vessel coronary artery disease were considered for
inclusion into the study. The exclusion criteria were as
follows: single graft, redo-CABG, evolving myocardial
infarction and concomitant valve surgery. After giving
written informed consent patients were randomised into
the trial. Patients were followed up at 6 weeks post sur-
gery and then annually for up to 10 years. The main
outcome is survival but patients are also being followed
up for myocardial infarctions, angina symptoms, strokes
or any other clinical adverse events [10].
ART is supported by grants from the Medical
Research Council (MRC) and the British Heart Founda-
tion (BHF). In the original funding application to the
MRC and BHF, centres from the UK, Italy and Australia
were identified as potential centres. However, once the
study was underway, other centres from Austria, Poland,
Brazil and India also expressed an interest in
participating.
All centres in ART received a training visit from a
member of the co-ordinating centre (CTEU, Royal
Brompton Hospital, London, UK) where the require-
ments for data collection, completion of the CRFs and
management of the data were described in a standar-
dised format. These visits ensured that the investigators
at each site (including principal investigator, co-investi-
gators and co-ordinators) fully understood the Protocol
and the practical procedures for the study described in
the Manual of Operations and the importance of con-
ducting the study to Good Clinical Practice (GCP).
S t u d ys i t ec o - o r d i n a t o r sw e r eresponsible for gathering
and recording data, and handling and resolving any edit
queries.
Data collection in ART is based on a paper system
with central monitoring of the data. A two-part no-car-
bon required (NCR) CRF was created to collect baseline,
in-hospital surgical information and follow-up data. The
participating centres were required to complete the rele-
vant CRF pages, tear off the top copy and then send
these pages to the CTEU by post or fax within the obli-
gatory timelines (Table 1). On receipt of these data, the
CTEU would review and log all data into the database
in the first instance. Data would then be entered into a
bespoke database system. If any inconsistent, missing, or
Table 1 Trial phases and time frame for receipt of study
documentation
Trial Documents Time Frame
Screening data Mailed to CTEU within 17 days of randomisation
In-hospital data Mailed to CTEU within 17 days of the surgery
6 week follow-up Mailed to CTEU within 17 days of follow up visit
Annual follow-
ups
Mailed to CTEU within 17 days of follow up visit
Edit queries Faxed to CTEU within 3 weeks of receipt
Adverse event
form
Faxed to CTEU within 72 hours of knowledge of the
event
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Each data query would request clarification of either
one or more data points. Each query would be sent by
fax to the centre for resolution. The participating cen-
tres were given a deadline of 3 weeks to return the cor-
rected data by fax to CTEU. In the event of not
receiving this information, centres would be sent a
reminder to send these data. On receipt of the corrected
information, the CTEU would then update the database
with the appropriate information and then the query
would be closed.
As described above, our main hypothesis was that
neither recruitment rates nor data quality and time
delay in sending the data are dependent on the socio-
economic status of the country of the participating site.
In this observational study, to test the hypothesis we
performed an analysis based on the 2 page CRF that
should be completed at the 6 week follow-up. Overdue
6 week data would be chased at 60 days post randomi-
sation (42 days + 17 days for completion and postage of
the CRF pages to the CTEU. The data-points from the 6
week follow-up CRF pages formed the basis for the
assessment of the data query generation and are shown
in Additional file 1. CRF pages were reviewed and cate-
gorised into “clean” and “dirty”. A clean CRF was classi-
fied as one with no edit queries on first receipt. Each
CRF page was classified separately. Each variable from
the two pages was categorised into either “no edit query
raised”,o r“edit query raised”. If any data were incom-
plete, inconsistent or illegible, CTEU raised a data query
requesting the centre to clarify the data. The timelines
were assessed on the basis of the time interval from the
6 week follow-up visit and receipt of complete (verified)
CRF at CTEU (Table 2).
The number of data queries raised per patient (counting
a maximum of one data query per CRF variable) was
counted. The percentage of data queries per patient was
then calculated based on the number of 42 possible
queries to be generated in total (see Additional file 1).
CRFs for all patients were analysed and presented in the
results. The number of recruited participants was estab-
lished on the basis of the date of first patient enrolled as
the reference date. Only whole months of enrolment in
the analysis were included. Rate of recruitment were
expressed as the number of patients enrolled per month.
Statistical analysis
Our primary goal was a comparison of recruitment rates
and data quality between countries. Data quality was
defined as the number of data queries (in percent) and
time delay (in days) between 6 week follow-up visit and
receipt of correct data. Analyses were stratified on the
basis of the socio-economic level into two categories:
“Developing” countries (Poland, Brazil and India) and
“Developed” (Italy, UK, Austria and Australia), according
to the World Bank data [11]. We also assessed the
impact of enrolment on the number of data queries and
time elapsed between 6-week visit and receipt of data.
Variables are shown as arithmetic mean and standard
deviation (for normally distributed quantitative vari-
ables) or median (Me) and interquartile range (IQR) (for
non-normally distributed quantitative data), or percent
(for qualitative data). Correlation between quantitative
variables was determined on the basis on Spearman
rank coefficients. Between-group comparisons were per-
formed using Mann-Whitney U-test. Normality of distri-
bution for continuous data was verified by Shapiro-Wilk
W-test. Non-normally distributed data underwent loga-
rithmic transformation before further analyses. ‘P’ value
< 0.05 was considered statistically significant.
Results
In the ART trial 3102 patients were randomised within
28 centres in 7 countries over 42 months. There were
18 centres (with 2326 randomised patients) in the
“Developed” and 10 centres (with 676 randomised
patients) in the “Developing” countries.
The total recruitment period was 42 months. Only 6
centres recruited patients for 3 years or more. The med-
ian number of months for recruitment was 28 per cen-
tre (minimum 3, maximum 42) (32 for ‘Developed’ and
23 for ‘Developing’; p < 0.001). The median recruitment
by centre was 94 patients (minimum 6, maximum 427)
with no significant difference between “Developed” and
“Developing” countries (96 patients and 78 patients,
respectively).
The overall recruitment rate was 4.4 patients per
month per centre (minimum 1.8, maximum 12.1). There
Table 2 Timelines established to assess time gap
between 6-week visit and receipt of data









6 week follow-up visit
II
Data received Data received
II
Data entered into a
database





Data entered into a
database
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ber of recruited patients by centres in the participating
countries (R
2 = 0.53, p < 0.001) (Figure 1).
The median time interval from 6 week follow-up visit
and receipt of complete CRF was 14 days (IQR: 7, 34)
and the median percent of data queries was 21% (IQR:
5, 48).
We found no correlation between the median time
elapsed between 6-week visit and receipt of data, and
the number of recruited patients by country (R
2 = 0.003,
p = ns). There was also no correlation between the
median percent of data queries per country and the
number of recruited patients (R
2 = 0.04, p = ns). Finally,
there was no correlation between the median percent of
data queries and the median time elapsed between 6-
week visit and receipt of data by country (R
2 = 0.02, p =
ns).
The number of recruited patients did not differ statis-
tically significantly by economic level ("Developing”
countries median: 83 persons/country, “Developed”
countries median: 98 persons/country) (Figure 2) as well
as the rate of enrolment ("Developing” countries med-
ian: 4.1 persons/month, “Developed” countries median:
3.7 persons/month) (Figure 3).
The time elapsed between 6-week visit and receipt of
data per country by economic level in shown in Figure
4. Time interval was significantly longer for “Develop-
ing” countries (median: 37 days) compared to “Devel-
oped” ones (median: 11 days) (p < 0.001).
The percent of data queries in a 6-week follow-up
visit per country was higher in “Developed” countries
(median: 23%) compared to “Developing” ones (med-
ian: 19%) but the difference was not significant (Figure
5) (p = ns).
Discussion
The socioeconomic status of the country did not appear
to influence the numbers of patients recruited or the
rate of recruitment. The timeliness of the data was
slower from “Developing” countries rather than “Devel-
oped” and did not seem to affect the number of edit
q u e r i e sa n dt h en u m b e ro fp a t i e n t se n r o l l e dd o e sn o t
seem to affect the number of edit queries or the timeli-
ness of the data. Those centres with the highest rate of
enrolment were those who enrolled the most number of
patients.
The data from this study provide some reassurance to
those designing and managing multi centre trials that
using a wide variety of centres with different socioeco-
nomic status does not appear to adversely affect the
quality of data as assessed by the number of data
queries. The inclusion of multiple centres worldwide
provides a number of advantages, in particular ensuring
Figure 1 Scatter diagram. Scatter diagram for correlation between
the rate of enrolment and the number of recruited patients by
country.
Figure 2 Impact of economic level. Impact of economic level on
the number of recruited patients per country.
Figure 3 Impact of economic level on the rate of enrolment.
Impact of economic level on the rate of enrolment (per month/
centre) per country.
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ing the findings of the study to be applicable to future
patients worldwide. However, there are a number of
potential challenges to consider when including centres
worldwide. These are cultural differences, and the varia-
bility of resources to carry out both the surgery and
completion of study related tasks including completing
the CRFs and following patients up properly. In ART
we also have to consider communication issues both
between the co-ordinating centre and the participating
centres and also between the centres and the patients
including reliability of postal systems and access to tele-
phones for follow-up. Additionally centres need to fol-
low up patients if they are admitted to other hospitals
and the systems to do this and obtain the necessary
medical summaries are variable.
We searched Medline for other clinical trials that had
evaluated data quality and found three trials although
none were exactly related to our analyses. One of these
trials was an oncologic international trial conducted in
the Netherlands and Indonesia. The authors showed
that using an electronic medical records system helped
to reduce data error rates, especially those critical for
the primary goals of the trial [12]. They also found that
during the study period the quality of data improved.
Out of 433 CRFs submitted for the first time 33.7%
needed some corrections but none of them had more
than 2 errors in the primary data. Five months after the
start of study the error rate for the primary data items
was just 1.6%. It needs to be clarified that the analysis
included only 2 countries so generalisation of its find-
ings is limited.
In the second study, Tolmie and colleagues assessed
the data quality submitted to the Clinical Endpoint
Committee for adjudication [13]. They assessed the
information submitted in the packages to the Commit-
tee for the endpoint events from 25 countries. Data
quality was rather poor. They found that 782 queries
were generated in 1595 endpoint packages reviewed
amongst which 78.9% generated only one query. Inter-
estingly, no source data queries were generated for
countries with no more than 25 recruited subjects, but
both low recruiting and high recruiting countries had a
high number of queries relating to subject identifiers.
The time between the query being submitted to the
sponsor and being resolved ranged from one day to 22.8
weeks (Median 23, IQR 1.61) [13].
In the third study, the Type 1 Diabetes Genetics Con-
sortium Trial, the authors reported good data quality
with a low percentage of missing data and low duplicate
data entry error rate (up to 0.5%) [14]. Using an electro-
n i cd a t ae n t r ys y s t e mt h e yf o u n ds o m ed i f f e r e n c e si n
data collection between 214 participating centres. The
highest rate of errors was found for Asia-Pacific coun-
tries and the United Kingdom, and the lowest was in
European and North American centres.
To address the potential challenges of involving multi-
ple centres worldwide Aitken et al. suggested multidi-
mensional strategies are used to administer such a trial.
They found that the approaches include using experi-
enced project coordinators, increasing communication
between centres, implementation of strategies to opti-
mise intervention compliance, site-specific recruitment
and retention techniques, centralisation of data manage-
ment and consideration of ethical and budgetary
requirements at local sites [15]. Frank et al. recom-
mended that to ensure high recruitment goals and high
quality of study it is necessary to have bilingual
Figure 4 Impact of economic level on time elapsed.I m p a c to f
economic level on time elapsed (in days) between 6-week visit and
receipt of data per country.
Figure 5 Impact of economic level on the percent of data
queries. Impact of economic level on the percent of data queries
in a 6-week follow-up visit per country. values are Me, IQR (box),
range (whiskers), and extreme values (dots).
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another’s sites, make use of frequent conference-call
staff meetings and be flexible within the bounds of the
sometimes contradictory requirements of the local
authorities [16]. At a site level a collaborative relation-
ship between researcher and practice staff is an impor-
tant issue for recruitment and retention, and for data
quality [17]. The factors responsible for good perfor-
mance of the trial are also study leadership and experi-
ence of clinical centre staff. So establishing an
organizational structure that provide leadership, site-to-
site communication, understandable performance cri-
teria, a proper process for data monitoring and provid-
ing feedback may guarantee success of the clinical trial
[18].
There are some limitations of our current study. First,
we use a paper-based system to complete data and to
validate their quality. Medical record abstraction is the
most significant source of errors and should be mea-
sured and managed appropriately and in a timely fash-
ion during the course of the trial. Researchers and co-
ordinating centres are transitioning from paper systems
to electronic data capture which are successfully inte-
grated into clinical practise and are believed to be of
higher quality compared with paper based systems [19].
Moreover there are many attempts to quantify data
quality for clinical trials using electronic data collection
that give reproducible quality control and make trials
more valid and scientifically stringent [5,7,15,20]. At the
co-ordinating centre for ART, the CTEU performed
central monitoring of data to ensure consistency and
completeness of dataset. Second, in our analysis we
grouped centres by country and then by socioeconomic
status without focusing on data on individual centres
which may have masked wide variation in data quality
within countries. However this method was used inten-
tionally to guarantee anonymity between centres. Finally,
this paper focuses only on 6 week data which is close to
the date of surgery. On the one hand, it is convenient to
eliminate difficulties with patient follow up (i.e. bias
caused by lost-to-follow-up). But on the other hand we
cannot exclude that annual follow up may provide dif-
ferent results, and this should be investigated in further
studies.
Conclusions
This study provides evidence that in a large multi-centre
trial, rates of recruitment, total recruitment and data
quality can be comparable between centres from “devel-
oped” and “developing countries”. Close attention
should be paid to the training of centres and to the cen-
tral management of data quality. Data may be received
in a less timely fashion from developing countries and
appropriate systems should be instigated to minimize
any delays. Achieving accurate and timely data is an
essential step in the good conduct of a clinical trial.
Additional material
Additional file 1: Data points from the 6 week visit CRF to be used
in the edit query analysis
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